🇺🇸 FDA
Pipeline program

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)

221458

Phase 1 other active

Quick answer

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD) for Systemic Lupus Erythematosus is a Phase 1 program (other) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline Biologicals S.A.
Indication
Systemic Lupus Erythematosus
Phase
Phase 1
Modality
other
Status
active

Clinical trials